Skip to content
Screener

Immunome IMNM Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
-$189.52M-200%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$20.96M-17,370%

Other financials

Income statement

See full
Revenue--100%
Operating income-$78.1M-68.1%
Net income-$73.1M-68.5%
EPS (diluted)-$0.65-30.0%

Balance sheet

See full
Cash & equivalents$217.7M+51.3%
Total debt$4.7M+14.4%
Total equity$525.1M+95.0%
Total assets$565.4M+90.8%

Cash flow

See full
Operating cash flow-$61.7M-24.9%
CapEx$2.2M+140%
Free cash flow-$63.9M-27.0%

Valuation

See full
Market cap$2.83B+237%
Enterprise value$2.62B+274%

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-64%-11.2pp
Debt / equity0.0×
Current ratio15.1×+3.0×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Immunome’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344636
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income5,0083,08110,5006,077
Net loss$(73,127)$(43,397)$(126,966)$(85,037)
Net loss per share, basic and diluted$(0.65)$(0.50)$(1.12)$(1.02)
Weighted-average shares outstanding, basic and diluted113,272,93187,010,742113,205,26083,231,544
Comprehensive loss:
Net loss$(73,127)$(43,397)$(126,966)$(85,037)
Unrealized loss on marketable securities(333)(21)(333)(81)
Comprehensive loss$(73,460)$(43,418)$(127,299)$(85,118)

Item 1. Financial Statements.

FAQ

What is Immunome's comprehensive income (loss), net of tax, attributable to parent?
Immunome (IMNM) reported comprehensive income (loss), net of tax, attributable to parent of -$73.46M in Q2 2026.
How has Immunome's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Immunome's comprehensive income (loss), net of tax, attributable to parent decreased by 69.2% year-over-year, from -$43.42M to -$73.46M.
What is the long-term trend for Immunome's comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2022 to 2025), Immunome's comprehensive income (loss), net of tax, attributable to parent has grown at a 78.2% compound annual growth rate (CAGR), from -$37.52M to -$212.45M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric captures all changes in equity during a period resulting from transactions and other events from non-owner sources, excluding net income. It includes items such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance beyond traditional accounting profit or loss.

Ask your AI about Immunome's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude